ArrowMark Colorado Holdings (PMVP) holds 3.67% stake in PMV Pharmaceuticals

Rhea-AI Filing Summary

ArrowMark Colorado Holdings, LLC reports beneficial ownership of 1,959,579 shares of PMV Pharmaceuticals, Inc. common stock, representing 3.67% of the class as of 06/30/2026.

The filing amends a Schedule 13G and states ArrowMark has sole voting and sole dispositive power over all 1,959,579 shares.

Insights

Institutional Ownership Analyst

ArrowMark holds a non-controlling 3.67% stake in PMV Pharmaceuticals as of 06/30/2026.

Large holders filing a Schedule 13G typically indicate passive investment intent rather than an activist approach. The report shows 1,959,579 shares beneficially owned with both sole voting and dispositive power, which signals direct control over voting decisions for this position.

Because the position is under 5%, it remains within the passive/beneficial-ownership reporting bucket and does not by itself trigger control presumptions under the filing.

Regulatory Compliance Officer

The amendment updates regulatory disclosure details and confirms the reporting entity and address.

The Schedule 13G/A lists ArrowMark Colorado Holdings, LLC (Delaware) as the reporting person and provides an address in Denver, Colorado. The signature block is by the Chief Compliance Officer dated 07/10/2026, consistent with an amended filing after the 06/30/2026 reporting date.

This is a routine ownership disclosure; material change monitoring would depend on future movements above the 5% threshold or shifts in voting/dispositive power.

Key Figures

Shares beneficially owned: 1,959,579 Percent of class: 3.67% Reporting date: 06/30/2026

3 metrics

Shares beneficially owned 1,959,579 Amount beneficially owned as stated in Item 4(a)

Percent of class 3.67% Percent of class as stated in Item 4(b)

Reporting date 06/30/2026 Date associated with the filing header

Key Terms

Schedule 13G/A, beneficially owned, sole dispositive power

3 terms

Schedule 13G/A regulatory

"Amendment No. 3 ) PMV Pharmaceuticals, Inc. Common stock"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned regulatory

"Item 4. | Ownership (a) | Amount beneficially owned: 1,959,579"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"7 | Sole Dispositive Power 1,959,579.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/10/2026 - 11:41 AM Accepted by SEC EDGAR 07/10/2026 - 11:40 AM Learn about SEC filing dates

FAQ

How many PMVP shares does ArrowMark Colorado Holdings report owning?

ArrowMark reports beneficial ownership of 1,959,579 shares of PMV Pharmaceuticals common stock in the Schedule 13G/A.

What percentage of PMV Pharmaceuticals does ArrowMark's stake represent?

The filing states the holding represents 3.67% of the outstanding common stock of PMV Pharmaceuticals as reported.

As of what date is the reported ownership measured?

The Schedule 13G/A ties the reported ownership to 06/30/2026, with the amendment signature dated 07/10/2026.

Does ArrowMark have voting or dispositive power over the shares?

Yes; the filing states ArrowMark has sole voting power and sole dispositive power over all 1,959,579 shares reported.

Is this filing a passive disclosure or an active control signal?

This Schedule 13G/A indicates a passive beneficial ownership filing for a position under 5%, consistent with a non-control disclosure.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

PMV Pharmaceuticals, Inc.

(Name of Issuer)

Common stock, par value $0.00001

(Title of Class of Securities)

69353Y103

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 69353Y103

1

Names of Reporting Persons

ArrowMark Colorado Holdings, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,959,579.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,959,579.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,959,579.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.67 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PMV Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 400 ALEXANDER PARK DRIVE, SUITE 301, PRINCETON, NJ, 08540
Item 2.
(a)	Name of person filing: ArrowMark Colorado Holdings, LLC
(b)	Address or principal business office or, if none, residence: 100 Fillmore Street, Suite 325, Denver, Colorado 80206
(c)	Citizenship: Delaware, United States
(d)	Title of class of securities: Common stock, par value $0.00001
(e)	CUSIP No.: 69353Y103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,959,579
(b)	Percent of class: 3.67%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,959,579
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,959,579
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ArrowMark Colorado Holdings, LLC

Signature:	Richard Grove
Name/Title:	Richard Grove | Chief Compliance Officer
Date:	07/10/2026